

Attorney Docket No.: J3692(C)
Serial No.: 10/531,155
Filed: September 26, 2005
Confirmation No.: 4686

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of Claims:

Claim 1: (Currently Amended) A composition for topical application to the scalp comprising

- (i) 0.1 to 5% by wt. of an anti-dandruff agent;
- (ii) 0.01 to 5% by wt. of conjugated linoleic acid; and
- (iii) a cosmetically acceptable diluent or carrier, wherein the anti-dandruff agent is selected from metal pyrrithiones, climbazole, ketoconazole and octopirox.

Claim 2: (Original) A composition as claimed in Claim 1, which is a shampoo.

Claim 3: (Original) A composition as claimed in Claim 1, which is a lotion or cream for direct application to the scalp.

Claim 4: (Original) A composition as claimed in Claim 1, wherein the anti-dandruff agent is zinc pyrithione.

Claims 5-6: (Cancelled)

Claim 7: (Currently Amended) A system for treating dandruff comprising: a first component comprising 0.1 to 5% by wt. of an anti-dandruff agent selected from

Attorney Docket No.: J3692(C)
Serial No.: 10/531,155
Filed: September 26, 2005
Confirmation No.: 4686

metal pyrrithiones, climbazole, ketoconazole and octopirox; and a second component comprising 0.01 to 5% by wt. of conjugated linoleic acid, wherein said first component and said second component are for topical application to the scalp and are in separate compartments within said system.

Claim 8: (Previously Presented) A method of treating dandruff which comprises applying to the scalp a composition of Claim 1.

Claim 9: (Cancelled)

Claim 10: (Previously Presented) A method of treating scalp itch which comprises applying to the scalp a composition of Claim 1.

Claim 11: (Cancelled)

Claim 12: (Previously Presented) A composition according to claim formulation as a transparent or opaque emulsion, lotion, cream, paste or gel, for treating scalp itch.

Claim 13 (Currently Amended) A composition according to claim 1 wherein at least 20% of the total GLA conjugated linoleic acid present in the composition is in the form of cis 9, trans 11 and/or trans 10, cis 12 isomers.